References
Cook S, Vermersch P, Comi G et al (2011) Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 17:578–593. https://doi.org/10.1177/1352458510391344
Jacobs BM, Ammoscato F, Giovannoni G et al (2018) Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry 89:1266–1271
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2 Epub 2017 Dec 21
Porwal MH, Salter A, Patel D, Obeidat AZ (2022) Alopecia in multiple sclerosis patients treated with disease modifying therapies. J Cent Nerv Syst Dis 14:11795735221109674. https://doi.org/10.1177/11795735221109674
Rolfes L, Pfeuffer S, Hackert J et al (2021) Skin reactions in patients with multiple sclerosis receiving cladribine treatment. Neurol Neuroimmunol Neuroinflamm 8:e990
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
The study is approved by the Institutional Review Board Clinic of Neurology, University Clinical Center of Serbia.
Informed consent
The patient signed informed consent.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Budimkic, M.S., Ivanovic, J., Momcilovic, N. et al. Eyebrow alopecia associated with cladribine treatment for multiple sclerosis. Neurol Sci 44, 3735–3736 (2023). https://doi.org/10.1007/s10072-023-06874-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06874-x